Vemurafenib Redifferentiation of BRAF Mutant, RAI-Refractory Thyroid Cancers

CONTEXT: BRAF(V600E) mutant thyroid cancers are often refractory to radioiodine (RAI). OBJECTIVES: To investigate the utility and molecular underpinnings of enhancing lesional iodide uptake with the BRAF inhibitor vemurafenib in patients with RAI-refractory (RAIR). DESIGN: This was a pilot trial tha...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Endocrinol Metab
Autors principals: Dunn, Lara A, Sherman, Eric J, Baxi, Shrujal S, Tchekmedyian, Vatche, Grewal, Ravinder K, Larson, Steven M, Pentlow, Keith S, Haque, Sofia, Tuttle, R Michael, Sabra, Mona M, Fish, Stephanie, Boucai, Laura, Walters, Jamie, Ghossein, Ronald A, Seshan, Venkatraman E, Ni, Ai, Li, Duan, Knauf, Jeffrey A, Pfister, David G, Fagin, James A, Ho, Alan L
Format: Artigo
Idioma:Inglês
Publicat: Endocrine Society 2018
Matèries:
Clinical Research Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6435099/
https://ncbi.nlm.nih.gov/pubmed/30256977
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/jc.2018-01478
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars